Performance analysis of Eliem Therapeutics (CLYM)
Annual Return
Over the past 3 years, CLYM has had an average annual return of +52.46%, outperforming the benchmark SPY, which returned +22.45% annual.
Since Aug 10, 2021, CLYM has had an average annual return of -8.36%, underperforming the benchmark SPY, which returned +13.22% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| +160.97% | +122.26% | -33.33% | -26.43% | -64.92% | -34.21% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +11.72% | +59.98% | -4.20% | +29.64% | +23.42% | -4.74% | +160.97% | ||||||
| 2025 | +5.57% | -23.68% | -15.90% | +9.91% | -11.98% | +5.12% | +12.95% | +59.25% | -9.91% | +1.98% | -7.76% | +111.61% | +122.26% |
| 2024 | -5.18% | +6.65% | +0.35% | +158.79% | +8.75% | -7.77% | +16.59% | -15.69% | -27.18% | -24.84% | -15.59% | -44.26% | -33.33% |
| 2023 | -4.64% | +1.73% | -18.54% | +8.28% | -7.04% | -4.08% | -4.26% | -1.13% | -0.78% | +0% | -2.66% | +5.47% | -26.43% |
| 2022 | -13.57% | -0.33% | -6.88% | -62.35% | +21.24% | -21.17% | +5.32% | -3.75% | +5.51% | +1.28% | -21.73% | +43.35% | -64.92% |
| 2021 | +61.57% | -30.01% | -3.11% | -17.40% | -27.30% | -34.21% |
Drawdown analysis of Eliem Therapeutics (CLYM)
The maximum drawdown for the CLYM was -96.05%, occurring on Apr 8, 2025. This drawdown has not yet recovered.
The current CLYM drawdown is -63.51%.
Since Aug 10, 2021 CLYM has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 2 times
- 10% or more: 2 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -96.05% | Sep 7, 2021 | 900 | Apr 8, 2025 | Ongoing | Ongoing | Ongoing |
| -29.96% | Aug 11, 2021 | 2 | Aug 13, 2021 | 8 | Aug 25, 2021 | 10 |
| -8.25% | Aug 30, 2021 | 1 | Aug 31, 2021 | 4 | Sep 7, 2021 | 5 |